){kind=logo}
- AboutOpenClose
- TeamOpenClose
- CareersOpenClose
- Strategy & FundsOpenClose
- Kineticos Capital Partners FundOpenClose
- Kineticos Disruptor FundOpenClose
- Kineticos AMR Accelerator FundOpenClose
- FoundryOpenClose
- PortfolioOpenClose
- MediaOpenClose
)
Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through Week 7, with…
){kind=logo}
Phase 1b/2a study in cystic fibrosis remains on track for full enrollment by end of 2025 following positive interim analysis…
May 15, 2025 – Research Triangle Park, NC – Kincell Bio announced the completion of a $22 million round, led by…
)
Kineticos Portfolio Company, Inceptor Bio, Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma…
){kind=logo}
Kineticos Launches Kinvard Bio to Advance Next-Generation Antibiotics in the Fight Against Antimicrobial Resistance Raleigh, North Carolina – February 24,…
Steve Gelone Joins Kineticos as a Strategic Advisor for Kineticos AMR Accelerator Fund I (KAMRA I) Raleigh, North Carolina –…
Lloyd Payne Joins Kineticos as Venture Partner for Kineticos AMR Accelerator Fund I (KAMRA I) Raleigh, North Carolina – January…
Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund COLUMBUS, Ohio – January 28, 2025 – Clarametyx Biosciences Inc. (“Clarametyx”), a clinical…
Kincell Bio Welcomes Industry Veteran Mark R. Bamforth as Chief Executive Officer to Drive Business Growth Research Triangle Park,…